Supplementary Table S2 from Safety, immunologic and clinical activity of Durvalumab in combination with Olaparib or Cediranib in advanced leiomyosarcoma: Results of the DAPPER clinical trial
Authors:
- Abdulazeez SalawuASAbdulazeez Salawu
- Ben X. WangBWBen X. Wang
- Ming HanMHMing Han
- Caryn GeadyCGCaryn Geady
- Alya HeiraliAHAlya Heirali
- Hal K. BermanHBHal K. Berman
- Thomas D. PfisterTPThomas D. Pfister
- Alberto Hernando-CalvoAHAlberto Hernando-Calvo
- Esmail Mutahar. Al-EzziEAEsmail Mutahar. Al-Ezzi
- Lee-Anne StaynerLSLee-Anne Stayner
- Abha A. GuptaAGAbha A. Gupta
- Olubukola AyodeleOAOlubukola Ayodele
Open Access
- 16 September 2024
- other
- Published by American Association for Cancer Research (AACR)